VIVEbiotech
VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) founded in 2015 in San Sebastian, Spain, exclusively specialized in lentiviral vector development and manufacturing for gene and cell therapy developers globally. The company operates a 3,000 sq.m. facility with seven cleanrooms, serving 60+ biotech and pharma clients across ex vivo and in vivo applications.
- Company typePrivate
- Founded2015
- HeadquartersSan Sebastian, Spain
- Headcount101–250
- GTM typeB2B
- OfferingServices
What VIVEbiotech does
VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) founded in 2015 and headquartered in San Sebastian, Spain, specializing exclusively in lentiviral vector development and manufacturing for gene and cell therapy applications. The company operates a 3,000 sq.m. state-of-the-art GMP-compliant manufacturing facility with seven dedicated cleanrooms and bioreactor production capacity ranging from 4 to 200 m2 (with 600 m2 expansion planned). Its proprietary technology platform encompasses stable producer cell line generation, custom lentiviral vector development with clonal activities and pseudotyping strategies, upstream and downstream process optimization, and the newly launched EvoLVcell platform for scalable production. The company holds GMP certification since 2017 and operates under both EMA and FDA regulatory standards, with in-house Qualified Person oversight for lot release.
The company's service portfolio covers the full development lifecycle: early-phase process development, R&D manufacturing, engineering and GMP lot production, fill/finish operations, analytical testing and release, stability studies, and regulatory documentation support for IMPD and IND submissions. VIVEbiotech serves both ex vivo (cell therapy, including CAR-T and TCR-NK) and in vivo (gene therapy) administration routes. Its customer base spans 60+ biotech and pharmaceutical companies globally across the US, Europe, Asia, and Australia, including named enterprise clients such as Galápagos, Xyphos (Astellas), Theravectys, and Zelluna Immunotherapy. The team of 130-140+ employees includes more than 85% advanced degree holders with 30+ years of combined virology experience.
VIVEbiotech generates revenue through project-based CDMO contracts priced by development stage, production scale, vector type, and service scope. The company employs a direct B2B enterprise sales model supported by active participation in major industry conferences (BIO International, ASGCT, ESGCT) and scientific publications. In December 2024, VIVEbiotech secured a growth equity investment from Ampersand Capital Partners (a healthcare-focused PE firm with over $3B AUM) to scale manufacturing capacity, with Dr. Stefan Beyer, former CEO of Vibalogics, appointed as Chairman. The company has manufactured over 200 batches in bioreactors and currently has 10+ in vivo lentiviral vector programs, several already in clinical phase, signaling expansion into higher-value gene therapy segments.
VIVEbiotech firmographics
Firmographics- Name
- VIVEbiotech
- Legal name
- VIVEBIOTECH S.L.
- Website
- https://vivebiotech.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) founded in 2015 in San Sebastian, Spain, exclusively specialized in lentiviral vector development and manufacturing for gene and cell therapy developers globally. The company operates a 3,000 sq.m. facility with seven cleanrooms, serving 60+ biotech and pharma clients across ex vivo and in vivo applications.
- Ownership category
- akta.pro rank
VIVEbiotech industry classification
Industry- Product category
- Cell and Gene Therapy CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)
Keywords
Where VIVEbiotech is headquartered
LocationHeadquarters
- HQ city
- San Sebastian
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
VIVEbiotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- GMP CDMO Manufacturing Services: Contract Development and Manufacturing Organization providing process development, manufacturing and analytical testing for lentiviral vectors. Services include technology transfer, process development and optimization, R&D manufacturing in bioreactors, engineering lots, GMP lots, fill/finish, stability studies, and regulatory support (IMPD/IND). Revenue generated through project-based contracts with biotech and pharma companies developing gene and cell therapies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based CDMO pricing based on service scope |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
VIVEbiotech product offering
Product offeringCore offering
VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) that develops and manufactures clinical and commercial-grade lentiviral vectors for gene and cell therapy applications. Services span custom vector development, upstream and downstream process development, GMP manufacturing across multiple bioreactor scales, analytical testing and release, regulatory support for IMPD/IND submissions, and stability studies for both ex vivo and in vivo administration routes. The company serves biotech and pharmaceutical clients globally from its 3,000 m² GMP facility in San Sebastian, Spain.
Product overview
VIVEbiotech is a GMP CDMO specializing exclusively in lentiviral vector development and manufacturing for gene and cell therapy applications. The company operates as a single-focus CDMO providing end-to-end services from early-phase development through commercial supply. Their integrated service portfolio encompasses Custom Lentiviral Vector Development, Upstream Process Development (USP), Downstream Process Development (DSP), GMP Manufacturing, Analytical Testing & Release, Regulatory Support Services (IMPD/IND), and Stability Studies. Services are available for both ex vivo (cell therapy) and in vivo (gene therapy) administration routes. The company operates 7 dedicated cleanrooms in a 3,000 m² GMP facility in San Sebastian, Spain.
Differentiator
Problem solved
Functional benefit
Products and services
- Lentiviral Vector GMP Manufacturing (CDMO Services) Contract Development and Manufacturing Organization (CDMO) services for GMP-grade lentiviral vectors for both ex vivo and in vivo gene and cell therapy applications. Includes process development, manufacturing across multiple bioreactor scales (4, 8, 10, 30, 200 m², with 600 m² upcoming), analytical testing, and regulatory support. Targeted at biotech and pharmaceutical companies developing gene and cell therapies.
- Custom Lentiviral Vector Development Custom vector development services including producer cell line work, genetic modification for productivity and tropism, clonal activities from design to clonings for regulatory compliance, pseudotyping strategies, and transgene engineering for large-size genetic cargo. Targets gene and cell therapy developers needing tailored vector configurations.
- Upstream Process Development (USP) Upstream process development services covering cell expansion, bioreactor seeding conditions, transfection optimization, harvest conditions, and in-process controls to maximize productivity during lentiviral vector manufacturing. Targets CDMO clients requiring scalable, regulatory-compliant upstream workflows.
- Downstream Process Development (DSP) Downstream purification process optimization including chromatographic methods, tangential flow filtration (TFF), and fill and finish operations to maximize yield and product quality of lentiviral vectors. Targets CDMO clients requiring scalable, regulatory-compliant downstream workflows.
- GMP Analytical Testing & Release Quality control and analytical testing services for product release, including physicochemical, biochemical, molecular, and cell-based assays, with lot release by in-house Qualified Person. Targeted at CDMO clients requiring GMP-compliant analytical characterization of lentiviral vector products.
- Regulatory Support Services CMC documentation support for IMPD and IND submissions, including regulatory strategy, technical writing, and compliance with EMA and FDA requirements. Targeted at gene and cell therapy developers preparing clinical trial applications.
- Stability Studies Long-term and in-use stability studies for lentiviral vector products to support clinical and commercial shelf-life determination under defined storage conditions. Targeted at CDMO clients requiring regulatory-grade stability data for submissions.
- EvoLVcell Platform Technology platform for enhanced lentiviral vector production efficiency and scale-up. Targets CDMO clients requiring high-yield, scalable manufacturing of lentiviral vectors using stable producer cell line technology.
Quantifiable outcome
- Over 200 batches manufactured in bioreactor with capacity for 60+ batches per year
- +3 more outcomes
Companies that use VIVEbiotech
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
VIVEbiotech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
VIVEbiotech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ZellunacoreLong-standing partnership since 2018 for GMP manufacture of lentiviral vectors supporting TCR-NK therapy development targeting solid tumors. VIVEbiotech supports Zelluna's lead program ZI-MA4-1, the world's first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026. Partnership exemplifies VIVEbiotech's commitment to enabling next-generation cell therapies.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
VIVEbiotech competitors and assessment
Company assessmentDirect peers
- Vibalogics: Hamburg-based CDMO specializing in viral vectors (including lentiviral) for cell and gene therapy. VIVEbiotech's chairman Dr. Stefan Beyer previously served as CEO/President of Vibalogics (acquired by Recipharm in 2022), making it a closely comparable direct peer in the LVV CDMO niche.
- Yposkesi (SK Pharmteco): French viral vector CDMO focused on gene and cell therapy manufacturing, now part of SK Pharmteco. Directly comparable to VIVEbiotech as a specialized viral vector CDMO serving similar gene and cell therapy developers.
- Cobra Biologics (Charles River Laboratories): UK-based viral vector and plasmid DNA CDMO acquired by Charles River Laboratories. Directly comparable as a contract manufacturer of lentiviral vectors and plasmids for gene and cell therapy clinical and commercial supply.
- Cevec Pharmaceuticals: German manufacturer of viral vectors including lentiviral vectors derived from its proprietary packaging cell line technology. Directly comparable as a specialized viral vector CDMO for cell and gene therapy applications.
Emerging players
- Genezen: US-based viral vector CDMO focused on lentiviral and AAV manufacturing for gene therapy developers. Comparable to VIVEbiotech as an emerging specialized LVV manufacturer scaling capacity for clinical and commercial supply.
Broad incumbents
- AGC Biologics: Large global CDMO offering cell and gene therapy services including lentiviral vector manufacturing as part of a broader biologics portfolio. Comparable as a multi-modality incumbent competing in the LVV CDMO market; VIVEbiotech board member Patricio Massera previously held leadership roles at AGC.
- Catalent (Novo Holdings): Major global CDMO with significant cell therapy and viral vector manufacturing capabilities. Provides lentiviral-related services at scale and competes with VIVEbiotech for cell and gene therapy clients seeking broader-service CDMOs.
- Lonza: One of the largest global CDMOs offering cell and gene therapy services including viral vector manufacturing. Represents a broad incumbent competitor that VIVEbiotech differentiates against through its exclusive LVV specialization.
- WuXi Advanced Therapies (WuXi AppTec): Global CDMO arm of WuXi AppTec providing viral vector and cell therapy manufacturing including lentiviral vectors at scale. Competes with VIVEbiotech across geographies (notably Asia) with a broader service portfolio.
Others
- Polyplus (Sartorius): Supplier of upstream transfection reagents and plasmids critical to lentiviral vector manufacturing, now part of Sartorius. Comparable as an ecosystem enabler for LVV CDMOs rather than a direct competitor, but its adoption shapes the cost structure of LVV production.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
VIVEbiotech social profiles
Digital presenceVIVEbiotech compliance and trust
Trust signalCompliance5 records
VIVEbiotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
VIVEbiotech leadership team
Management profileNumber of profiles
Profiles11 records
VIVEbiotech funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VIVEbiotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VIVEbiotech
What does VIVEbiotech do?
VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) that develops and manufactures clinical and commercial-grade lentiviral vectors for gene and cell therapy applications. Services span custom vector development, upstream and downstream process development, GMP manufacturing across multiple bioreactor scales, analytical testing and release, regulatory support for IMPD/IND submissions, and stability studies for both ex vivo and in vivo administration routes. The company serves biotech and pharmaceutical clients globally from its 3,000 m² GMP facility in San Sebastian, Spain.
Is VIVEbiotech a public or private company?
VIVEbiotech is a private company. It is classified as private equity controlled and is currently operating.
When was VIVEbiotech founded?
VIVEbiotech was founded in 2015. It employs 101 to 250 people.
Where is VIVEbiotech based?
VIVEbiotech is headquartered in San Sebastian, Spain, in the Europe region.
How does VIVEbiotech make money?
One revenue line is on record: GMP CDMO Manufacturing Services.
Who are VIVEbiotech's main competitors?
Direct peers on record are Vibalogics, Yposkesi (SK Pharmteco), Cobra Biologics (Charles River Laboratories) and Cevec Pharmaceuticals. Genezen is listed as an emerging player. Broad incumbents are AGC Biologics, Catalent (Novo Holdings), Lonza and WuXi Advanced Therapies (WuXi AppTec). Polyplus (Sartorius) is listed as an others.
Does VIVEbiotech have an API?
No public API is recorded for VIVEbiotech.
What industry is VIVEbiotech in?
VIVEbiotech's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services. Its NAICS code is 325414 and its SIC code is 2834.